ORIGINAL RESEARCH PAPER
Volume - 14 | Issue - 10 | October - 2025 | PRINT ISSN No. 2277 - 8179 | DOI : 10.36106/ijsr
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH

PATHOLOGICAL FEATURES OF INVASIVE LOBULAR CARCINOMA AND THEIR IMPACT ON SURGICAL DECISION-MAKING

General Surgery

Dr K. S. Goel	Department of General Surgery, SGT Medical College and Hospital, Budhera, Gurgaon, NCR Delhi- 122505
Dr Shyam Goyal	Department of General Surgery, SGT Medical College and Hospital, Budhera, Gurgaon, NCR Delhi- 122505
Dr Tarun Gupta	Department of General Surgery, SGT Medical College and Hospital, Budhera, Gurgaon, NCR Delhi- 122505
Dr Milan Patel*	Department of General Surgery, SGT Medical College and Hospital, Budhera, Gurgaon, NCR Delhi- 122505 *Corresponding Author
Dr Nishant Manhas	Department of General Surgery, SGT Medical College and Hospital, Budhera, Gurgaon, NCR Delhi- 122505
Dr Pawan Yadav	Department of General Surgery, SGT Medical College and Hospital, Budhera, Gurgaon, NCR Delhi- 122505
Dr Pawan Tiwari	Department of General Surgery, SGT Medical College and Hospital, Budhera, Gurgaon, NCR Delhi- 122505

ABSTRACT

Invasive lobular carcinoma (ILC) represents the second most common form of invasive breast cancer, accounting for approximately 10-15% of all invasive breast malignancies. Unlike invasive ductal carcinoma (IDC), ILC exhibits distinct pathological features that significantly influence surgical planning and treatment outcomes. This paper examines the unique morphological characteristics of ILC, including its growth pattern, cellular architecture, and molecular profile, and analyzes how these features impact surgical decision-making processes. The single-file growth pattern and lack of desmoplastic response characteristic of ILC often result in underestimation of tumor size on imaging modalities, leading to higher rates of positive margins and re-excision procedures. Additionally, the propensity for multifocal and multicentric disease presentation in ILC necessitates careful consideration of surgical approach, with many cases requiring mastectomy over breast-conserving surgery. This review synthesizes current literature on ILC pathology and provides evidence-based recommendations for optimizing surgical management strategies.

KEYWORDS

Invasive Lobular Carcinoma, Breast Cancer, Surgical Oncology, Pathology, Tumor Margins

INTRODUCTION

Invasive lobular carcinoma (ILC) constitutes a distinct histological subtype of breast cancer with unique biological and clinical characteristics that differentiate it from the more common invasive ductal carcinoma (IDC). First described by Foote and Stewart in 1941, ILC has garnered increasing attention due to its specific growth patterns and clinical behavior that pose unique challenges in diagnosis, staging, and surgical management (Foote & Stewart, 1941; McCart Reed et al., 2015).

The incidence of ILC has been steadily increasing over the past several decades, with current estimates suggesting it represents 10-15% of all invasive breast cancers (Li et al., 2003; Pestalozzi et al., 2008). This increase has been attributed to improved diagnostic techniques, increased awareness among pathologists, and possibly to the widespread use of hormone replacement therapy, given ILC's strong association with estrogen receptor positivity (Dossus et al., 2010).



https://doi.org/10.1016/j.critrevonc.2020.103174

The clinical significance of ILC extends beyond its epidemiological importance. The distinctive pathological features of ILC, including its characteristic single-file growth pattern, lack of cohesive cell architecture, and tendency for extensive local spread, create specific challenges in surgical planning and execution (Fortunato et al., 2009). These features often result in discordance between clinical examination, imaging findings, and actual tumor extent, leading to higher rates of positive surgical margins and subsequent re-excision procedures compared to IDC (Hussien et al., 2006).

Understanding the pathological basis of these clinical challenges is crucial for optimizing surgical outcomes in patients with ILC. This paper aims to provide a comprehensive review of the pathological features that define ILC and examine how these characteristics directly impact surgical decision-making processes, from initial treatment planning through final margin assessment.

Pathological Features of Invasive Lobular Carcinoma

Morphological Characteristics

The hallmark pathological feature of ILC is its distinctive growth pattern, characterized by single cells or small clusters of cells arranged in a linear, single-file configuration infiltrating through breast tissue (Rosen, 2001). This growth pattern, known as the "Indian file" arrangement, represents a fundamental difference from IDC, which typically grows in cohesive clusters or sheets of cells with associated desmoplastic reaction.

At the microscopic level, ILC cells demonstrate several characteristic features. The individual tumor cells are typically small to medium-sized with relatively uniform, round to oval nuclei and inconspicuous nucleoli (Ellis et al., 2004). The cytoplasm is usually scant and may contain intracytoplasmic lumina, a feature that, while not pathognomonic, is more commonly observed in ILC than in IDC. The lack of cellular cohesion in ILC is attributed to the loss or reduction of E-cadherin expression, a key adhesion molecule that maintains cell-cell junctions (Berx et al., 1995).

The growth pattern of ILC has significant implications for tumor detection and size assessment. Unlike IDC, which typically forms a discrete mass with reactive fibrosis, ILC infiltrates between normal breast structures without causing significant architectural distortion or desmoplastic response (Fortunato et al., 2009). This characteristic allows ILC to reach considerable size while maintaining the overall breast architecture, making it particularly challenging to detect on clinical examination and conventional imaging modalities.



https://www.nature.com/articles/modpathol201035

Molecular Profile and Biomarker Expression

ILC exhibits a distinct molecular profile that differs significantly from IDC and has important implications for both prognosis and treatment selection. The most characteristic molecular feature of ILC is the consistent loss of E-cadherin expression, which occurs in approximately 85-95% of cases (Dabbs et al., 2007). This loss is typically the result of mutations in the CDH1 gene, which encodes E-cadherin, or epigenetic silencing through promoter hypermethylation (Berx et al., 1998).

The hormone receptor profile of ILC shows a strong predilection for estrogen receptor (ER) and progesterone receptor (PR) positivity, with approximately 85-95% of cases expressing ER and 60-70% expressing PR (Li et al., 2003). This high rate of hormone receptor positivity is significantly greater than that observed in IDC and has important implications for adjuvant therapy selection. Conversely, HER2 overexpression is relatively uncommon in ILC, occurring in only 5-10% of cases, compared to approximately 15-20% in IDC (Pestalozzi et al., 2008).

Recent molecular profiling studies using gene expression arrays have revealed that ILC predominantly falls within the luminal A and luminal B intrinsic subtypes, consistent with its hormone receptor expression pattern (Zhao et al., 2004). However, ILC demonstrates some unique gene expression patterns, including upregulation of genes involved in cell motility and invasion, which may contribute to its characteristic growth pattern and metastatic behavior (Korkola et al., 2003).



https://www.denvaxindia.com/blog/types-of-lobular-breast-cancer/



https://www.denvaxindia.com/blog/types-of-lobular-breast-cancer/

Variants of Invasive Lobular Carcinoma

While classic ILC represents the most common form, several histological variants have been recognized, each with distinct morphological features and clinical implications. The pleomorphic variant of ILC is characterized by larger cells with more nuclear pleomorphism and higher-grade features compared to classic ILC (Eusebi et al., 1992). This variant tends to have a higher proliferation rate, may be more likely to be hormone receptor-negative, and generally carries a worse prognosis than classic ILC.

The solid variant of ILC maintains the characteristic loss of E-cadherin expression but grows in solid sheets rather than the typical single-file pattern (Martinez & Azzopardi, 1979). This variant can be particularly challenging to distinguish from high-grade IDC and may require immunohistochemical confirmation of E-cadherin loss for definitive diagnosis.

Other less common variants include the alveolar variant, characterized by groups of cells arranged in alveolar or acinar patterns, and the tubulolobular variant, which shows features of both lobular and tubular carcinoma (Ellis et al., 2004). Each variant may have different implications for surgical planning, as their growth patterns and tendency for multifocal disease may vary.

Impact on Imaging and Preoperative Assessment

Mammographic Challenges

The unique growth pattern of ILC creates significant challenges for mammographic detection and assessment. Unlike IDC, which typically presents as a spiculated mass with associated architectural distortion, ILC often manifests as subtle mammographic findings or may be mammographically occult (Butler et al., 1999). When visible on mammography, ILC may appear as an ill-defined mass, focal asymmetry, or architectural distortion without a discrete mass.

The lack of desmoplastic response in ILC contributes to its subtle mammographic appearance. The single-file growth pattern allows tumor cells to infiltrate between normal breast structures without causing the characteristic spiculation and architectural distortion typically associated with malignancy (Hilleren et al., 1991). This results in lower sensitivity of mammography for ILC detection, with studies reporting sensitivities ranging from 34% to 79%, compared to 85-93% for IDC (Butler et al., 1999).

Furthermore, when ILC is detected mammographically, there is often significant underestimation of tumor size. The lack of a discrete tumor-stromal interface makes it difficult to determine the true extent of disease, leading to discrepancies between mammographic size estimates and final pathological measurements (Hilleren et al., 1991).

Magnetic Resonance Imaging Considerations

Magnetic resonance imaging (MRI) has emerged as a valuable tool in the evaluation of ILC, offering superior sensitivity for detection and size assessment compared to conventional imaging modalities. The enhanced soft tissue contrast and ability to detect areas of abnormal enhancement make MRI particularly useful for ILC evaluation (Rodenko et al., 1996).

Studies have consistently demonstrated that MRI provides more

accurate size assessment of ILC compared to mammography and ultrasound. Boetes et al. (1995) reported that MRI measurements correlated more closely with final pathological size in ILC patients, with improved accuracy in detecting multifocal and multicentric disease. The ability of MRI to detect non-mass enhancement patterns, which are common in ILC, contributes to its superior performance in this setting.

However, MRI findings in ILC can be variable and sometimes challenging to interpret. ILC may present as mass enhancement, non-mass enhancement, or a combination of both patterns (Mann et al., 2008). The non-mass enhancement pattern, characterized by regional or segmental enhancement without a discrete mass, is particularly common in ILC and may represent the imaging correlate of the tumor's infiltrative growth pattern.

Ultrasound Limitations

Ultrasound evaluation of ILC presents unique challenges related to the tumor's growth characteristics. The lack of significant desmoplastic response and the infiltrative nature of ILC often result in subtle sonographic findings that may be overlooked or misinterpreted (Butler et al., 1999). When visible on ultrasound, ILC typically appears as an ill-defined, hypoechoic area with posterior acoustic shadowing, but these findings may be less conspicuous than those typically seen with IDC.

The sensitivity of ultrasound for ILC detection varies widely in the literature, ranging from 68% to 98%, depending on the study population and ultrasound technique employed (Berg et al., 2004). Size assessment by ultrasound also tends to underestimate tumor dimensions in ILC, although this underestimation is generally less pronounced than with mammography.

Surgical Challenges and Decision-Making

Margin Assessment Difficulties

One of the most significant surgical challenges posed by ILC relates to margin assessment and the achievement of clear surgical margins. The infiltrative growth pattern of ILC, characterized by single cells extending well beyond the main tumor mass, makes it difficult to determine the true extent of disease both intraoperatively and on final pathological examination (Hussien et al., 2006).

Studies have consistently demonstrated higher positive margin rates in ILC compared to IDC. Hussien et al. (2006) reported positive margin rates of 27% for ILC versus 16% for IDC in patients undergoing breast-conserving surgery. This disparity has been attributed to the difficulty in grossly identifying the tumor edges during surgery and the tendency for ILC to extend beyond what is apparent on frozen section examination.

The definition and assessment of surgical margins in ILC also present unique challenges. The single-file growth pattern means that individual tumor cells may extend considerable distances from the main tumor mass, making it difficult to determine what constitutes an adequate margin width (Biglia et al., 2017). Current guidelines recommend the same margin standards for ILC as for IDC (no ink on tumor), but some experts advocate for wider margins in ILC given its growth characteristics.

Re-excision Rates and Factors

The combination of imaging limitations and margin assessment challenges in ILC translates to significantly higher re-excision rates compared to IDC. Multiple studies have reported re-excision rates for ILC ranging from 20% to 50%, compared to 10-20% for IDC (Molland et al., 2004; Singletary et al., 2002).

Several factors contribute to the increased re-excision rates in ILC. The underestimation of tumor size on preoperative imaging leads to inadequate initial excision volumes. The difficulty in achieving clear margins due to the infiltrative growth pattern necessitates additional tissue removal. Additionally, the tendency for multifocal and multicentric disease in ILC may require conversion to mastectomy if multiple positive margins are encountered (Molland et al., 2004).

The impact of re-excision on patient outcomes extends beyond the immediate surgical considerations. Multiple surgical procedures increase healthcare costs, delay adjuvant therapy initiation, and may compromise cosmetic outcomes. Understanding these factors is crucial for surgical planning and patient counseling in ILC cases.

Breast-Conserving Surgery Considerations

The decision between breast-conserving surgery (BCS) and mastectomy in ILC patients requires careful consideration of multiple factors related to the tumor's pathological characteristics. The tendency for ILC to present as multifocal or multicentric disease influences surgical planning, as extensive disease may preclude breast conservation (Molland et al., 2004).

Studies examining the feasibility of BCS in ILC have yielded variable results. While some reports suggest comparable local recurrence rates between ILC and IDC patients treated with BCS, others have raised concerns about higher recurrence rates in ILC patients (Sastre-Garau et al., 1996; Silverstein et al., 1994). These discrepancies may be related to differences in patient selection, surgical technique, and adjuvant therapy administration.

The role of preoperative MRI in surgical planning for ILC has been the subject of considerable debate. While MRI provides superior tumor size assessment and can detect multifocal/multicentric disease, studies examining its impact on surgical decision-making have shown mixed results (Turnbull et al., 2010). Some studies suggest that MRI use leads to increased mastectomy rates without improving local control, while others demonstrate benefits in selected patient populations.

Sentinel Lymph Node Biopsy Considerations

The performance of sentinel lymph node biopsy (SLNB) in ILC patients requires consideration of the tumor's biological characteristics and potential impact on lymphatic drainage patterns. While the technical aspects of SLNB are similar between ILC and IDC, some studies have suggested differences in success rates and accuracy (Fortunato et al., 2009).

The success rate of SLNB in ILC patients has been reported to be comparable to that in IDC patients, with identification rates exceeding 95% in most series (Fortunato et al., 2009). However, some studies have raised concerns about higher false-negative rates in ILC patients, potentially related to the tumor's growth pattern and its interaction with lymphatic vessels.

The pattern of lymph node involvement in ILC may also differ from that seen in IDC. ILC has been associated with a higher frequency of contralateral axillary lymph node involvement and internal mammary chain involvement, although the clinical significance of these findings remains unclear (Arpino et al., 2004).

Treatment Implications and Outcomes

Adjuvant Therapy Considerations

The distinct molecular profile of ILC has important implications for adjuvant therapy selection and treatment outcomes. The high frequency of hormone receptor positivity in ILC makes endocrine therapy a cornerstone of adjuvant treatment for most patients (Li et al., 2003). However, some studies have suggested that ILC may be less responsive to certain endocrine therapies compared to IDC, although the clinical significance of these findings remains debated.

The low frequency of HER2 overexpression in ILC means that most patients will not benefit from HER2-targeted therapies such as trastuzumab (Pestalozzi et al., 2008). This has implications for treatment planning and patient counseling, as the range of available targeted therapies may be more limited compared to other breast cancer subtypes.

Chemotherapy sensitivity in ILC has been the subject of considerable investigation. Some studies suggest that ILC may be less responsive to chemotherapy compared to IDC, particularly to anthracycline-based regimens (Mathieu et al., 2004). However, the clinical significance of these findings and their impact on treatment recommendations remain areas of active research.

Long-term Outcomes and Prognosis

The long-term outcomes of ILC patients have been extensively studied, with most reports suggesting a prognosis that is comparable to or slightly better than IDC when matched for stage and other prognostic factors (Li et al., 2003; Pestalozzi et al., 2008). However, ILC demonstrates some unique patterns of recurrence and metastasis that have important clinical implications.

ILC has been associated with a tendency for late recurrence, with some studies reporting continued risk of recurrence beyond 10 years after

initial diagnosis (Arpino et al., 2004). This pattern of late recurrence has implications for long-term surveillance strategies and duration of adjuvant endocrine therapy.

The pattern of distant metastasis in ILC also differs from that seen in IDC, with ILC showing a predilection for involvement of the gastrointestinal tract, peritoneum, and reproductive organs (Arpino et al., 2004). This unique metastatic pattern may have implications for surveillance strategies and symptom recognition in long-term survivors.

Quality of Life and Cosmetic Outcomes

The impact of ILC's pathological characteristics on quality of life and cosmetic outcomes following breast-conserving surgery is an important consideration in surgical decision-making. The higher re-excision rates associated with ILC may compromise cosmetic outcomes and patient satisfaction (Molland et al., 2004).

Studies examining cosmetic outcomes following BCS for ILC have yielded variable results. While some reports suggest comparable cosmetic outcomes between ILC and IDC patients, others have noted inferior results related to the need for wider excisions and higher re-excision rates (Singletary et al., 2002). These considerations should be incorporated into preoperative counseling and surgical planning discussions.



https://www.denvaxindia.com/blog/types-of-lobular-breast-cancer/

Future Directions and Research Opportunities

Emerging Imaging Techniques

The limitations of conventional imaging modalities in ILC assessment have spurred interest in emerging imaging techniques that may improve detection and characterization. Digital breast tomosynthesis (DBT) has shown promise in improving mammographic detection of ILC by reducing tissue overlap and enhancing visualization of architectural distortion (Spangler et al., 2011).

Contrast-enhanced mammography and dedicated breast CT are other emerging modalities that may offer advantages in ILC evaluation. These techniques combine the high spatial resolution of mammography with contrast enhancement capabilities, potentially improving both detection and size assessment of ILC (Dromain et al., 2011).

Molecular imaging approaches, including positron emission tomography (PET) with various tracers, represent another area of active investigation. These techniques may provide functional information about tumor biology that complements anatomical imaging findings (Kumar et al., 2006).

Molecular Diagnostics and Personalized Treatment

Advances in molecular diagnostics offer the potential for more personalized treatment approaches in ILC patients. Gene expression profiling and next-generation sequencing technologies are providing new insights into the molecular heterogeneity within ILC and may identify subgroups with different prognosis and treatment sensitivities (McCart Reed et al., 2015).

The development of circulating tumor DNA (ctDNA) assays may offer new opportunities for monitoring treatment response and detecting recurrence in ILC patients. Given the challenges in imaging assessment of ILC, molecular monitoring approaches may prove particularly valuable in this patient population (Dawson et al., 2013).

Liquid biopsy approaches, including circulating tumor cells and exosome analysis, represent other areas of active investigation that may provide insights into ILC biology and treatment response (Pantel & Speicher, 2016).

Surgical Innovation and Techniques

Technological advances in surgical techniques may help address some of the challenges associated with ILC management. Intraoperative imaging modalities, including specimen radiography and ultrasound, may improve margin assessment during surgery (Bathla et al., 2011).

The development of intraoperative pathological assessment techniques, including rapid immunohistochemistry for E-cadherin, may help distinguish ILC from IDC during surgery and guide margin assessment strategies (Tot, 2003).

Oncoplastic surgical techniques may offer opportunities to achieve wider excision margins while maintaining acceptable cosmetic outcomes in ILC patients. These approaches combine oncological principles with plastic surgical techniques to optimize both cancer control and aesthetic results (Clough et al., 2003).

CONCLUSIONS

Invasive lobular carcinoma represents a distinct breast cancer subtype with unique pathological features that significantly impact surgical decision-making and patient management. The characteristic single-file growth pattern, loss of E-cadherin expression, and infiltrative nature of ILC create specific challenges in detection, staging, and surgical treatment that differentiate it from invasive ductal carcinoma.

The limitations of conventional imaging modalities in ILC assessment, combined with the tumor's tendency for extensive local spread, result in higher rates of positive surgical margins and re-excision procedures. These challenges necessitate careful preoperative planning, consideration of advanced imaging techniques such as MRI, and thorough patient counseling regarding the potential need for additional surgical procedures.

The distinct molecular profile of ILC, characterized by high rates of hormone receptor positivity and low rates of HER2 overexpression, has important implications for adjuvant therapy selection. While most ILC patients will benefit from endocrine therapy, the relative insensitivity to some systemic treatments compared to IDC remains an area of active investigation.

Future advances in imaging technology, molecular diagnostics, and surgical techniques hold promise for improving outcomes in ILC patients. The development of more sensitive detection methods, personalized treatment approaches based on molecular profiling, and innovative surgical techniques may help address the current challenges in ILC management.

Understanding the unique pathological features of ILC and their clinical implications is essential for optimizing surgical outcomes and improving patient care. Continued research into the biology of ILC and the development of tailored management strategies will be crucial for advancing care for patients with this challenging breast cancer subtype.

REFERENCES

1. Arpino, G., Bardou, V. J., Clark, G. M., & Elledge, R. M. (2004). Infiltrating lobular carcinoma of the breast: Tumor characteristics and clinical outcome. Breast Cancer Research, 6(3), R149-R156. https://doi.org/10.1186/bcr767
2. Bathla, L., Harris, A., Davey, M., Sharma, P., & Silva, E. (2011). High resolution intraoperative two-dimensional specimen mammography and its impact on second operation for re-excision of positive margins at final pathology after breast conservation surgery. American Journal of Surgery, 202(4), 387-394. https://doi.org/10.1016/j.amjsurg.2010.09.031
3. Berg, W. A., Gutierrez, L., NessAiver, M. S., Carter, W. B., Bhargavan, M., Lewis, R. S., & Ioffe, O. B. (2004). Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology, 233(3), 830-849. https://doi.org/10.1148/radiol.2333031484
4. Berx, G., Cleton-Jansen, A. M., Nollet, F., de Leeuw, W. J., van de Vijver, M., Cornelisse, C., & van Roy, F. (1995). E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO Journal, 14(24), 6107-6115. https://doi.org/10.1002/j.1460-2075.1995.tb00301.x
5. Berx, G., Cleton-Jansen, A. M., Strumane, K., de Leeuw, W. J., Nollet, F., van Roy, F., & Cornelisse, C. (1998). E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene, 16(15), 1919-1925. https://doi.org/10.1038/sj.onc.1201901

6. Biglia, N., Bounous, V. E., Martincich, L., Panuccio, E., Liberale, V., Ottino, L., ... & Menada, M. V. (2017). Role of MRI (magnetic resonance imaging) versus conventional imaging for breast cancer presurgical staging in young women or with dense breast. European Journal of Surgical Oncology, 43(8), 1581-1589. https://doi.org/10.1016/j.ejso.2017.05.011
7. Boetes, C., Mus, R. D., Holland, R., Barentsz, J. O., Strijk, S. P., Wobbes, T., ... & Ruijs, S. H. (1995). Breast tumors: Comparative accuracy of MR imaging and mammography. Radiology, 196(3), 631-638. https://doi.org/10.1148/radiology.196.3.7644624
8. Butler, R. S., Venta, L. A., Wiley, E. L., Ellis, R. L., Dempsey, P. J., & Rubin, E. (1999). Sonographic evaluation of infiltrating lobular carcinoma. American Journal of Roentgenology, 172(2), 325-330. https://doi.org/10.2214/ajr.172.2.9930780
9. Clough, K. B., Lewis, J. S., Couturaud, B., Fitoussi, A., Nos, C., & Falcou, M. C. (2003). Oncoplastic techniques allow extensive resections for breast-conserving therapy of breast carcinomas. Annals of Surgery, 237(1), 26-34. https://doi.org/10.1097/00000658-200301000-00005
10. Dabbs, D. J., Schnitt, S. J., Geyer, F. C., Weigelt, B., Baehner, F. L., Decker, T., ... & Reis-Filho, J. S. (2007). Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. American Journal of Surgical Pathology, 31(12), e1-e8. https://doi.org/10.1097/PAS.0b013e31815e8e6a
11. Dawson, S. J., Tsui, D. W., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S. F., ... & Caldas, C. (2013). Analysis of circulating tumor DNA to monitor metastatic breast cancer. New England Journal of Medicine, 368(13), 1199-1209. https://doi.org/10.1056/NEJMoa1213261
12. Dossus, L., Benusiglio, P. R., Lobbedez, T., de la Rochefordiere, A., Thiebaut, A., Delaloge, S., ... & Spielmann, M. (2010). Tissue concentrations of steroids and risk of breast cancer in postmenopausal women. Cancer Epidemiology, Biomarkers & Prevention, 19(10), 2532-2541. https://doi.org/10.1158/1055-9965.EPI-10-0312
13. Dromain, C., Thibault, F., Muller, S., Rimareix, F., Delaloge, S., Tardivon, A., & Balleyguier, C. (2011). Dual-energy contrast-enhanced digital mammography: Initial clinical results. European Radiology, 21(3), 565-574. https://doi.org/10.1007/s00330-010-1944-y
14. Ellis, I. O., Galea, M., Broughton, N., Locker, A., Blamey, R. W., & Elston, C. W. (2004). Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology, 20(6), 479-489. https://doi.org/10.1111/j.1365-2559.1992.tb01032.x
15. Eusebi, V., Magalhaes, F., & Azzopardi, J. G. (1992). Pleomorphic lobular carcinoma of the breast: An aggressive tumor showing apocrine differentiation. Human Pathology, 23(6), 655-662. https://doi.org/10.1016/0046-8177(92)90321-s
16. Foote, F. W., & Stewart, F. W. (1941). Lobular carcinoma in situ: A rare form of mammary cancer. American Journal of Pathology, 17(4), 491-496.
17. Fortunato, L., Mascaro, A., Poccia, I., Andrich, R., Telera, S., Florindi, C., ... & Farina, M. (2009). Lobular breast cancer: Same survival and local control compared with ductal cancer, but should both be treated the same way? Analysis of an institutional database over a 10-year period. Annals of Surgical Oncology, 16(6), 1478-1485. https://doi.org/10.1245/s10434-009-0456-9
18. Hilleren, D. J., Andersson, I. T., Lindholm, K., & Linnell, F. S. (1991). Invasive lobular carcinoma: Mammographic findings in a 10.year experience. Radiology, 178(1), 149-154. https://doi.org/10.1148/radiology.178.1.1984295
19. Hussien, M., Lioe, T. F., Finnegan, J., Spence, R. A., & Maxwell, P. (2006). Surgical treatment for invasive lobular carcinoma of the breast. Breast, 15(2), 252-258. https://doi.org/10.1016/j.breast.2005.06.001
20. Korkola, J. E., DeVries, S., Fridlyand, J., Hwang, E. S., Estep, A. L., Chen, Y. Y., ... & Waldman, F. M. (2003). Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Research, 63(21), 7167-7175.
21. Kumar, R., Chauhan, A., Zhuang, H., Chandra, P., Schnall, M., & Alavi, A. (2006). Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Research and Treatment, 98(3), 267-274. https://doi.org/10.1007/s10549-006-9159-2
22. Li, C. I., Anderson, B. O., Daling, J. R., & Moe, R. E. (2003). Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA, 289(11), 1421-1424. https://doi.org/10.1001/jama.289.11.1421
23. Mann, R. M., Hoogeveen, Y. L., Blickman, J. G., & Boetes, C. (2008). MRI compared to conventional diagnostic work-up in the detection and evaluation of invasive lobular carcinoma of the breast: A review of existing literature. Breast Cancer Research and Treatment, 107(1), 1-14. https://doi.org/10.1007/s10549-007-9528-5
24. Martinez, V., & Azzopardi, J. G. (1979). Invasive lobular carcinoma of the breast: Incidence and variants. Histopathology, 3(6), 467-488. https://doi.org/10.1111/j.1365-2559.1979.tb03029.x
25. Mathieu, M. C., Rouzier, R., Llombart-Cussac, A., Sideris, L., Koscielny, S., Travagli, J. P., ... & Delaloge, S. (2004). The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. European Journal of Cancer, 40(3), 342-351. https://doi.org/10.1016/j.ejca.2003.08.015
26. McCart Reed, A. E., Kalinowski, L., Simpson, P. T., & Lakhani, S. R. (2015). Invasive lobular carcinoma of the breast: The increasing importance of this special subtype. Breast Cancer Research, 17(1), 127. https://doi.org/10.1186/s13058-015-0639-z
27. Molland, J. G., Donnellan, M., Janu, N. C., Carmalt, H. L., Kennedy, C. W., & Gillett, D. J. (2004). Infiltrating lobular carcinoma–a comparison of diagnosis, management and outcome with infiltrating duct carcinoma. Breast, 13(5), 389-396. https://doi.org/10.1016/j.breast.2004.03.004
28. Pantel, K., & Speicher, M. R. (2016). The biology of circulating tumor cells. Oncogene, 35(10), 1216-1224. https://doi.org/10.1038/onc.2015.192